Skip to main content
Premium Trial:

Request an Annual Quote

Patrick Sullivan

Premium
Patrick Sullivan has been elected to PerkinElmer’s board, the company said this week. Sullivan is executive chairman of Hologic. He was also chairman, president, and CEO of Cytyc, which merged with Hologic in October. Previously he had sales and marketing positions with Abbott Laboratories.
 

As part of his election to the board, Sullivan will receive $11,667 and a stock award of PerkinElmer common stock with a fair market value of $16,667, the company said in a document filed with the US Securities and Exchange Commission. He will also receive an initial one-time stock option grant of 10,000 shares of PerkinElmer stock.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.